Compare Moderna, Inc. (MRNA) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sirius XM Holdings Inc — how do they compare? Moderna, Inc. trades at $63.73 (market cap $24.18B), while Sirius XM Holdings Inc trades at $28.48 (market cap $9.70B). The key difference: Moderna, Inc. is far larger — about 2.5× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SIRI | |
|---|---|---|
Market Cap | $24.18B | $9.70B |
Sector | Health | Media |
52-Week High | $81.80 | $32.59 |
52-Week Low | $22.36 | $19.92 |
Enterprise Value | $20.33B | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Sirius XM Holdings (SIRI) trades at $28.40, down 1.32% with bearish technical signals despite attractive valuation metrics including P/E of 11.56 and P/B of 0.81. The company reported mixed Q2 2026 results with a revenue beat but earnings miss, while maintaining stable cash flow and announcing a $0.27 dividend. Recent news highlights satellite communications growth potential and institutional positioning.
SIRI presents a value opportunity with strong cash generation and dividend yield, though near-term headwinds include subscriber challenges and debt levels. Analyst consensus remains bullish with $33.17 price target representing 17% upside, but investors should monitor execution on subscriber retention and competitive pressures in the evolving audio streaming landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
